Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.
OncLive’s April Roundup of Key FDA Decisions in Oncology
Revisit the OncLive On Air Episodes From February 2024
Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC
FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC